Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 15/20 | 0.43 |
| ▸ | RORC | P51449 | 2/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19785976 | 0.90 | PTGDR2 (0.41) | PTGDR2RORCCCR1 | |
| SCHEMBL29613560 | 0.90 | PTGDR2 (0.41) | PTGDR2RORCCCR1 | |
| SCHEMBL19785964 | 0.86 | PTGDR2 (0.43) | PTGDR2RORCCCR1 | |
| SCHEMBL19785590 | 0.85 | PTGDR2 (0.44) | PTGDR2RORCCCR1KCNH2 | |
| SCHEMBL29613591 | 0.85 | PTGDR2 (0.44) | PTGDR2RORCCCR1KCNH2 | |
| SCHEMBL21368976 | 0.82 | PTGDR2 (0.42) | PTGDR2RORC | |
| SCHEMBL29613545 | 0.82 | PTGDR2 (0.42) | PTGDR2RORC | |
| SCHEMBL19785777 | 0.80 | RORC (0.50) | PTGDR2RORCCCR1KCNH2 | |
| SCHEMBL29613585 | 0.80 | RORC (0.35) | PTGDR2RORCCCR1KCNH2 | |
| SCHEMBL19785969 | 0.80 | RORC (0.35) | PTGDR2RORCCCR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934282-B2 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | LEO PHARMA A/S (DK) | 2021-03-02 | — | — | US | disclosed |
| US-20200291010-A1 | HETEROAROMATIC MDOULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA A/S | 2020-09-17 | — | — | US | disclosed |
| EP-3484880-B1 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA AS (DK) | 2020-09-02 | — | — | EP | disclosed |
| WO-2018011201-A1 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA A/S (DK) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291010-A1 | HETEROAROMATIC MDOULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | RXRA, RORA, NR1H3 | PTGDR2 328/4885RORC 18/4885CCR1 97/4885 |
| US-10934282-B2 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | RXRA, RXRG, RXRB | PTGDR2 434/4885RORC 17/4885CCR1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.